{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,31]],"date-time":"2026-01-31T05:55:20Z","timestamp":1769838920853,"version":"3.49.0"},"reference-count":30,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:00:00Z","timestamp":1560124800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,10]]},"DOI":"10.1007\/s10067-019-04626-x","type":"journal-article","created":{"date-parts":[[2019,6,10]],"date-time":"2019-06-10T00:02:35Z","timestamp":1560124955000},"page":"2757-2763","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":18,"title":["Association between seropositivity and discontinuation of tumor necrosis factor inhibitors due to ineffectiveness in rheumatoid arthritis"],"prefix":"10.1007","volume":"38","author":[{"given":"Yoshikazu","family":"Ogawa","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobunori","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Atsushi","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuji","family":"Hirano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasuhide","family":"Kanayama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuichiro","family":"Yabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Oguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayoshi","family":"Fujibayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Takagi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masahiro","family":"Hanabayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Koji","family":"Funahashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masatoshi","family":"Hayashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Tsuboi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shuji","family":"Asai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nobuyuki","family":"Asai","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takuya","family":"Matsumoto","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yasumori","family":"Sobue","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Toshihisa","family":"Kojima","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,6,10]]},"reference":[{"key":"4626_CR1","doi-asserted-by":"publisher","first-page":"2569","DOI":"10.1002\/art.27584","volume":"62","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO 3rd et al (2010) 2010 rheumatoid arthritis classification criteria: an american college of rheumatology\/european league against rheumatism collaborative initiative. Arthritis Rheum 62:2569\u20132581","journal-title":"Arthritis Rheum"},{"key":"4626_CR2","doi-asserted-by":"publisher","first-page":"15","DOI":"10.3109\/s10165-011-0486-8","volume":"22","author":"P Suwannalai","year":"2012","unstructured":"Suwannalai P, Trouw LA, Toes RE, Huizinga TW (2012) Anti-citrullinated protein antibodies (acpa) in early rheumatoid arthritis. Mod Rheumatol 22:15\u201320","journal-title":"Mod Rheumatol"},{"key":"4626_CR3","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1002\/art.40218","volume":"69","author":"C Orr","year":"2017","unstructured":"Orr C, Najm A, Biniecka M, McGarry T, Ng CT, Young F, Fearon U, Veale DJ (2017) Synovial immunophenotype and anti-citrullinated peptide antibodies in rheumatoid arthritis patients: relationship to treatment response and radiologic prognosis. Arthritis Rheumatol 69:2114\u20132123","journal-title":"Arthritis Rheumatol"},{"key":"4626_CR4","doi-asserted-by":"publisher","first-page":"1346","DOI":"10.1002\/art.39595","volume":"68","author":"JE Gottenberg","year":"2016","unstructured":"Gottenberg JE, Courvoisier DS, Hernandez MV, Iannone F, Lie E, Canhao H et al (2016) Brief report: association of rheumatoid factor and anti-citrullinated protein antibody positivity with better effectiveness of abatacept: results from the pan-european registry analysis. Arthritis Rheumatol 68:1346\u20131352","journal-title":"Arthritis Rheumatol"},{"key":"4626_CR5","doi-asserted-by":"publisher","DOI":"10.1136\/rmdopen-2017-000564","volume":"4","author":"D Jansen","year":"2018","unstructured":"Jansen D, Emery P, Smolen JS, Westhovens R, Le Bars M, Connolly SE et al (2018) Conversion to seronegative status after abatacept treatment in patients with early and poor prognostic rheumatoid arthritis is associated with better radiographic outcomes and sustained remission: post hoc analysis of the agree study. RMD Open 4:e000564","journal-title":"RMD Open"},{"key":"4626_CR6","first-page":"448","volume":"36","author":"AS Neubauer","year":"2018","unstructured":"Neubauer AS, Minartz C, Herrmann KH, Baerwald CGO (2018) Cost-effectiveness of early treatment of acpa-positive rheumatoid arthritis patients with abatacept. Clin Exp Rheumatol 36:448\u2013454","journal-title":"Clin Exp Rheumatol"},{"key":"4626_CR7","doi-asserted-by":"publisher","first-page":"1707","DOI":"10.1007\/s10067-014-2756-2","volume":"33","author":"M Cuchacovich","year":"2014","unstructured":"Cuchacovich M, Bueno D, Carvajal R, Bravo N, Aguillon JC, Catalan D et al (2014) Clinical parameters and biomarkers for anti-tnf treatment prognosis in rheumatoid arthritis patients. Clin Rheumatol 33:1707\u20131714","journal-title":"Clin Rheumatol"},{"key":"4626_CR8","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.jbspin.2013.01.004","volume":"80","author":"E Salgado","year":"2013","unstructured":"Salgado E, Campos J, Moreira-Navarrete V, Mulero J, Navarro F, Perez-Pampin E et al (2013) Rheumatoid factor does not predict response to tnf antagonists in rheumatoid arthritis: three centers experience. Joint Bone Spine 80:438\u2013440","journal-title":"Joint Bone Spine"},{"key":"4626_CR9","doi-asserted-by":"publisher","first-page":"1810","DOI":"10.1002\/art.39626","volume":"68","author":"M Ghiti Moghadam","year":"2016","unstructured":"Ghiti Moghadam M, Vonkeman HE, Ten Klooster PM, Tekstra J, van Schaardenburg D, Starmans-Kool M et al (2016) Stopping tumor necrosis factor inhibitor treatment in patients with established rheumatoid arthritis in remission or with stable low disease activity: a pragmatic multicenter, open-label randomized controlled trial. Arthritis Rheumatol 68:1810\u20131817","journal-title":"Arthritis Rheumatol"},{"key":"4626_CR10","doi-asserted-by":"publisher","first-page":"g5060","DOI":"10.1136\/bmj.g5060","volume":"349","author":"M Wolkewitz","year":"2014","unstructured":"Wolkewitz M, Cooper BS, Bonten MJ, Barnett AG, Schumacher M (2014) Interpreting and comparing risks in the presence of competing events. BMJ 349:g5060","journal-title":"BMJ"},{"key":"4626_CR11","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1161\/CIRCULATIONAHA.115.017719","volume":"133","author":"PC Austin","year":"2016","unstructured":"Austin PC, Lee DS, Fine JP (2016) Introduction to the analysis of survival data in the presence of competing risks. Circulation 133:601\u2013609","journal-title":"Circulation"},{"key":"4626_CR12","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000002512","volume":"95","author":"SF Weng","year":"2016","unstructured":"Weng SF, Chiu YH, Jan RL, Chen YC, Chien CC, Wang JJ, Chu CC (2016) Death does matter--cancer risk in patients with end-stage renal disease: a nationwide population-based study with competing risk analyses. Medicine 95:e2512","journal-title":"Medicine"},{"key":"4626_CR13","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1161\/CIRCULATIONAHA.115.018294","volume":"133","author":"CJ Shih","year":"2016","unstructured":"Shih CJ, Ou SM, Chao PW, Kuo SC, Lee YJ, Yang CY, Tarng DC, Lin CC, Huang PH, Li SY, Chen YT (2016) Risks of death and stroke in patients undergoing hemodialysis with new-onset atrial fibrillation: a competing-risk analysis of a nationwide cohort. Circulation 133:265\u2013272","journal-title":"Circulation"},{"key":"4626_CR14","doi-asserted-by":"publisher","first-page":"4391","DOI":"10.1002\/sim.7501","volume":"36","author":"PC Austin","year":"2017","unstructured":"Austin PC, Fine JP (2017) Practical recommendations for reporting fine-gray model analyses for competing risk data. Stat Med 36:4391\u20134400","journal-title":"Stat Med"},{"key":"4626_CR15","doi-asserted-by":"publisher","first-page":"339","DOI":"10.3109\/s10165-011-0518-4","volume":"22","author":"T Kojima","year":"2012","unstructured":"Kojima T, Kaneko A, Hirano Y, Ishikawa H, Miyake H, Oguchi T, Takagi H, Yabe Y, Kato T, Ito T, Terabe K, Fukaya N, Kanayama Y, Shioura T, Funahashi K, Hayashi M, Kato D, Matsubara H, Fujibayashi T, Kojima M, Ishiguro N, for the TBC (2012) Study protocol of a multicenter registry of patients with rheumatoid arthritis starting biologic therapy in Japan: Tsurumai biologics communication registry (tbcr) study. Mod Rheumatol 22:339\u2013345","journal-title":"Mod Rheumatol"},{"key":"4626_CR16","doi-asserted-by":"publisher","first-page":"1995","DOI":"10.1002\/art.38022","volume":"65","author":"KA Young","year":"2013","unstructured":"Young KA, Deane KD, Derber LA, Hughes-Austin JM, Wagner CA, Sokolove J, Weisman MH, Buckner JH, Mikuls TR, O'Dell JR, Keating RM, Gregersen PK, Robinson WH, Holers VM, Norris JM (2013) Relatives without rheumatoid arthritis show reactivity to anti-citrullinated protein\/peptide antibodies that are associated with arthritis-related traits: studies of the etiology of rheumatoid arthritis. Arthritis Rheum 65:1995\u20132004","journal-title":"Arthritis Rheum"},{"key":"4626_CR17","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/art.30100","volume":"63","author":"MP van der Linden","year":"2011","unstructured":"van der Linden MP, Knevel R, Huizinga TW, van der Helm-van Mil AH (2011) Classification of rheumatoid arthritis: comparison of the 1987 american college of rheumatology criteria and the 2010 american college of rheumatology\/european league against rheumatism criteria. Arthritis Rheum 63:37\u201342","journal-title":"Arthritis Rheum"},{"key":"4626_CR18","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1001\/jama.2013.281053","volume":"310","author":"World medical association declaration of helsinki","year":"2013","unstructured":"World medical association declaration of helsinki (2013) Ethical principles for medical research involving human subjects. Jama 310:2191\u20132194","journal-title":"Jama"},{"key":"4626_CR19","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1016\/j.rdc.2009.10.001","volume":"35","author":"J Fransen","year":"2009","unstructured":"Fransen J, van Riel PL (2009) The disease activity score and the eular response criteria. Rheum Dis Clin N Am 35:745\u2013757 vii-viii","journal-title":"Rheum Dis Clin N Am"},{"key":"4626_CR20","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1002\/1529-0131(199810)41:10<1845::AID-ART17>3.0.CO;2-K","volume":"41","author":"AM van Gestel","year":"1998","unstructured":"van Gestel AM, Haagsma CJ, van Riel PL (1998) Validation of rheumatoid arthritis improvement criteria that include simplified joint counts. Arthritis Rheum 41:1845\u20131850","journal-title":"Arthritis Rheum"},{"key":"4626_CR21","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1002\/sim.5762","volume":"32","author":"D Kuk","year":"2013","unstructured":"Kuk D, Varadhan R (2013) Model selection in competing risks regression. Stat Med 32:3077\u20133088","journal-title":"Stat Med"},{"key":"4626_CR22","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1016\/j.jmva.2015.10.001","volume":"143","author":"C Li","year":"2016","unstructured":"Li C (2016) The fine-gray model under interval censored competing risks data. J Multivar Anal 143:327\u2013344","journal-title":"J Multivar Anal"},{"key":"4626_CR23","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","volume":"48","author":"Y Kanda","year":"2013","unstructured":"Kanda Y (2013) Investigation of the freely available easy-to-use software 'ezr' for medical statistics. Bone Marrow Transplant 48:452\u2013458","journal-title":"Bone Marrow Transplant"},{"key":"4626_CR24","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/256534","volume":"2015","author":"A Mulat","year":"2015","unstructured":"Mulat A, Bayu H, Mellie H, Alemu A (2015) Induced second trimester abortion and associated factors in Amhara region referral hospitals. Biomed Res Int 2015:256534","journal-title":"Biomed Res Int"},{"key":"4626_CR25","doi-asserted-by":"publisher","first-page":"360","DOI":"10.1016\/j.jspd.2014.11.004","volume":"3","author":"E Acaroglu","year":"2015","unstructured":"Acaroglu E, Guler UO, Olgun ZD, Yavuz Y, Pellise F, Domingo-Sabat M, Yakici S, Alanay A, Perez-Grueso FS, Yavuz Y, European Spine Study Group (2015) Multiple regression analysis of factors affecting health-related quality of life in adult spinal deformity. Spine Deform 3:360\u2013366","journal-title":"Spine Deform"},{"key":"4626_CR26","doi-asserted-by":"publisher","first-page":"498","DOI":"10.1038\/nature24486","volume":"551","author":"MC Luo","year":"2017","unstructured":"Luo MC, Gu YQ, Puiu D, Wang H, Twardziok SO, Deal KR, Huo N, Zhu T, Wang L, Wang Y, McGuire PE, Liu S, Long H, Ramasamy RK, Rodriguez JC, van SL, Yuan L, Wang Z, Xia Z, Xiao L, Anderson OD, Ouyang S, Liang Y, Zimin AV, Pertea G, Qi P, Bennetzen JL, Dai X, Dawson MW, M\u00fcller HG, Kugler K, Rivarola-Duarte L, Spannagl M, Mayer KFX, Lu FH, Bevan MW, Leroy P, Li P, You FM, Sun Q, Liu Z, Lyons E, Wicker T, Salzberg SL, Devos KM, Dvo\u0159\u00e1k J (2017) Genome sequence of the progenitor of the wheat d genome aegilops tauschii. Nature 551:498\u2013502","journal-title":"Nature"},{"key":"4626_CR27","doi-asserted-by":"publisher","first-page":"1487","DOI":"10.1093\/rheumatology\/ker010","volume":"50","author":"R Klaasen","year":"2011","unstructured":"Klaasen R, Cantaert T, Wijbrandts CA, Teitsma C, Gerlag DM, Out TA et al (2011) The value of rheumatoid factor and anti-citrullinated protein antibodies as predictors of response to infliximab in rheumatoid arthritis: an exploratory study. Rheumatology (Oxford) 50:1487\u20131493","journal-title":"Rheumatology (Oxford)"},{"key":"4626_CR28","first-page":"1670","volume":"34","author":"L Mancarella","year":"2007","unstructured":"Mancarella L, Bobbio-Pallavicini F, Ceccarelli F, Falappone PC, Ferrante A, Malesci D, Massara A, Nacci F, Secchi ME, Manganelli S, Salaffi F, Bambara ML, Bombardieri S, Cutolo M, Ferri C, Galeazzi M, Gerli R, Giacomelli R, Grassi W, Lapadula G, Cerinic MM, Montecucco C, Trotta F, Triolo G, Valentini G, Valesini G, Ferraccioli GF, GISEA group (2007) Good clinical response, remission, and predictors of remission in rheumatoid arthritis patients treated with tumor necrosis factor-alpha blockers: the gisea study. J Rheumatol 34:1670\u20131673","journal-title":"J Rheumatol"},{"key":"4626_CR29","first-page":"497","volume":"33","author":"Y Braun-Moscovici","year":"2006","unstructured":"Braun-Moscovici Y, Markovits D, Zinder O, Schapira D, Rozin A, Ehrenburg M, Dain L, Hoffer E, Nahir AM, Balbir-Gurman A (2006) Anti-cyclic citrullinated protein antibodies as a predictor of response to anti-tumor necrosis factor-alpha therapy in patients with rheumatoid arthritis. J Rheumatol 33:497\u2013500","journal-title":"J Rheumatol"},{"key":"4626_CR30","doi-asserted-by":"publisher","first-page":"R61","DOI":"10.1186\/ar4498","volume":"16","author":"D Di Giuseppe","year":"2014","unstructured":"Di Giuseppe D, Discacciati A, Orsini N, Wolk A (2014) Cigarette smoking and risk of rheumatoid arthritis: a dose-response meta-analysis. Arthritis Res Ther 16:R61","journal-title":"Arthritis Res Ther"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04626-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-019-04626-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-019-04626-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,8]],"date-time":"2020-06-08T23:31:51Z","timestamp":1591659111000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-019-04626-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,6,10]]},"references-count":30,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2019,10]]}},"alternative-id":["4626"],"URL":"https:\/\/doi.org\/10.1007\/s10067-019-04626-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,6,10]]},"assertion":[{"value":"29 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 May 2019","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 May 2019","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 June 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"N.T. has received speaking fees from Abbott Japan Co. Ltd., Eisai Co. Ltd., Mitsubishi Tanabe Pharma Corporation, Bristol-Myers Squibb, Abbott Japan, Chugai Pharmaceutical Co. Ltd., and Pfizer Co. Ltd. N.I. has received lecture fees including service on speaker bureaus from Daiichi Sankyo Company Ltd., Takeda Pharmaceutical Co. Ltd., Taisho Toyama Pharmaceutical Co. Ltd., Kaken Pharmaceutical Co. Ltd., Eisai Co. Ltd., Janssen Pharmaceutical KK, Bristol-Myers Squibb, Abbott Japan, Chugai Pharmaceutical Co. Ltd., Mitsubishi Tanabe Pharmaceutical, UCB Japan, and Astellas Pharma Inc. T.K. has received lecture fees from Mitsubishi Tanabe Pharma Corporation, Takeda Pharma Corporation, Bristol-Myers Squibb, Abbott Japan, Chugai Pharmaceutical Co. Ltd., and Eisai Pharma Corporation. All other authors have declared no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}